title: RET codon 609 mutations: a contribution for better clinical managing.
abstract: Medullary thyroid carcinoma currently accounts for 5-8% of all thyroid cancers. The clinical course of this disease varies from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated with a high mortality rate. As many as 75% of all medullary thyroid carcinomas are sporadic, with an average age at presentation reported as 60 years, and the remaining 25% are hereditary with an earlier age of presentation, ranging from 20 to 40 years. Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases. RET mutations predispose an individual to the development of medullary thyroid carcinomas and can also influence the individual response to RET protein receptor-targeted therapies. RET codon 609 point mutations are rare genetic events belonging to the intermediate risk category for the onset of medullary thyroid carcinoma. A large genealogy resulting in a less aggressive form of medullary thyroid carcinoma is associated with the high penetrance of pheochromocytoma and has been reported in the literature. In this short review article, we comment on our previous report of a large multiple endocrine neoplasia type 2A kindred with the same Cys609Ser germline RET mutation in which, conversely, the syndrome was characterized by a slightly aggressive, highly penetrant form of medullary thyroid carcinoma that was associated with low penetrance of pheochromocytoma and primary hyperparathyroidism.
authors.affiliation: Department of Medicine, University of Padova, Padova, Italy.
authors.forename: Caterina
authors.initials: C
authors.lastname: Mian
authors.forename: Paola
authors.initials: P
authors.lastname: Sartorato
authors.forename: Susi
authors.initials: S
authors.lastname: Barollo
authors.forename: Mariangela
authors.initials: M
authors.lastname: Zane
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Opocher
mesh_terms: D018276:Carcinoma, Medullary / Q000235:genetics*; D018278:Carcinoma, Neuroendocrine; D003062:Codon / Q000235:genetics*; D003545:Cysteine / Q000235:genetics; D056726:Genetic Association Studies; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D006961:Hyperparathyroidism / Q000235:genetics; D007558:Italy; D018813:Multiple Endocrine Neoplasia Type 2a / Q000235:genetics*; D010375:Pedigree; D000090063:Proto-Oncogene Mas; D051096:Proto-Oncogene Proteins c-ret / Q000235:genetics*; D012694:Serine / Q000235:genetics; D013964:Thyroid Neoplasms / Q000235:genetics*
chemical_list: D003062:Codon; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D012694:Serine; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human; D003545:Cysteine